Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 401.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,253 shares of the company’s stock after purchasing an additional 78,656 shares during the period. SG Americas Securities LLC’s holdings in Trevi Therapeutics were worth $132,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Trevi Therapeutics by 2.3% during the third quarter. Vanguard Group Inc. now owns 1,957,875 shares of the company’s stock worth $4,268,000 after purchasing an additional 44,613 shares during the last quarter. American Century Companies Inc. acquired a new stake in Trevi Therapeutics during the third quarter worth about $47,000. Silverarc Capital Management LLC increased its position in Trevi Therapeutics by 4.7% during the third quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock worth $2,022,000 after purchasing an additional 41,491 shares during the last quarter. Deutsche Bank AG acquired a new stake in Trevi Therapeutics during the third quarter worth about $55,000. Finally, Barclays PLC acquired a new stake in Trevi Therapeutics during the second quarter worth about $34,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $2.58 on Thursday. Trevi Therapeutics, Inc. has a 1-year low of $0.97 and a 1-year high of $4.00. The stock has a market cap of $177.92 million, a PE ratio of -8.90 and a beta of 0.86. The firm has a 50-day simple moving average of $2.89 and a two-hundred day simple moving average of $1.97.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. As a group, sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TRVI has been the subject of several recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, April 9th. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target on shares of Trevi Therapeutics in a research report on Thursday, March 21st.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.